Device Trial Radar · NCT07922122
Transcutaneous Spinal Cord Stimulation Combined With 4-Aminopyridine and Intensive Rehabilitation in SCI
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
8
Planned (sponsor's estimate)
Start
Jun 6, 2026
Primary completion
Jul 8, 2027
Study completion Sep 8, 2027
Sponsor
- Lead sponsor
- TryAbility LLCAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Niche Biomedical, Inc. dba ANEUVO
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this prospective, single-arm pilot feasibility study is to evaluate the safety, feasibility, and preliminary functional outcomes of combining transcutaneous spinal cord stimulation (TSS), dalfampridine (4-aminopyridine), and intensive rehabilitation in adults with chronic spinal cord injury (SCI). The primary research question is whether this combined treatment approach can be safely and feasibly implemented in an outpatient neurorehabilitation setting. The study will also explore whether participants demonstrate improvements in upper and lower extremity motor function, muscle strength, walking ability, balance, and functional mobility following the intervention. Eight adults with chronic spinal cord injury will participate in a 12-week rehabilitation program at TRYAbility NeuroRecovery Center. Participants will attend approximately three treatment sessions per week, consisting of 60 minutes of physical therapy and 60 minutes of occupational therapy combined with noninvasive transcutaneous spinal cord stimulation using the ANEUVO ExaStim Stimulation System. All participants will be receiving dalfampridine prescribed by their treating physicians as part of routine medical care. The research team will not prescribe, administer, or adjust medication dosages. The primary outcomes will focus on participant recruitment, treatment attendance, intervention tolerability, and adverse events to assess the feasibility and safety of the combined approach. Secondary exploratory outcomes will examine changes in upper extremity motor function, hand dexterity, walking speed, walking endurance, balance, and functional mobility. Participants will undergo standardized clinical assessments at baseline, week 6, and week 12 to evaluate changes in functional performance over time. The findings will provide preliminary evidence regarding the feasibility, safety, and potential functional benefits of integrating spinal cord stimulation, physician-prescribed dalfampridine, and intensive rehabilitation. Results will help inform the design of larger controlled clinical trials investigating combined treatment approaches for motor recovery following chronic spinal cord injury.
Conditions
- Spinal Cord Injuries
Interventions
Transcutaneous spinal cord stimulationDevice
The intervention consists of noninvasive transcutaneous spinal cord stimulation (TSS) delivered using the ANEUVO ExaStim Stimulation System in combination with intensive, task-specific physical and occupational therapy in adults with chronic spinal cord injury who are receiving physician-prescribed dalfampridine (4-aminopyridine). Stimulation will be delivered through surface electrodes positioned over the cervical (C5-C7) and thoracolumbar (T11-L1) spinal regions, with abdominal reference electrodes. The stimulation waveform will consist of biphasic rectangular pulses, with pulse widths ranging from 500 to 2000 microseconds and frequencies of 0-100 Hz. Stimulation intensity will be individualized to produce visible motor activation without discomfort. Participants will receive approximately three treatment visits per week for 12 weeks. Each visit will include 60 minutes of occupational therapy and 60 minutes of physical therapy, including device setup. Transcutaneous spinal stimulat
Primary outcomes
What the sponsor says the trial is designed to measure.
- 10-Meter Walk Test (10MWT) 6-Minute Walk Test (6MWT) Berg Balance Scale (BBS) Upper Extremity Motor Score (UEMS) Capabilities of Upper Extremity Test (CUE-T)Time frame: Baseline, Week 6, and Week 12
- 6 minute walk testTime frame: baseline, week 6, and week 12
- Berg Balance ScaleTime frame: Baseline, week 6, and week 12
2 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
TryAbility Neuro Recovery Center
Downers Grove, Illinois · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.